Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Oedema peripheral? 149 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 149 reports of Oedema peripheral have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 0.4% of all adverse event reports for EMPAGLIFLOZIN.

149
Reports of Oedema peripheral with EMPAGLIFLOZIN
0.4%
of all EMPAGLIFLOZIN reports
15
Deaths
84
Hospitalizations

How Dangerous Is Oedema peripheral From EMPAGLIFLOZIN?

Of the 149 reports, 15 (10.1%) resulted in death, 84 (56.4%) required hospitalization, and 8 (5.4%) were considered life-threatening.

Is Oedema peripheral Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EMPAGLIFLOZIN. However, 149 reports have been filed with the FAERS database.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Urinary tract infection (1,439) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201)

What Other Drugs Cause Oedema peripheral?

AMBRISENTAN (2,959) TREPROSTINIL (2,816) ADALIMUMAB (2,356) LENALIDOMIDE (2,298) AMLODIPINE (2,076) PREDNISONE (2,029) METHOTREXATE (1,939) MACITENTAN (1,932) RITUXIMAB (1,698) TOCILIZUMAB (1,574)

Which EMPAGLIFLOZIN Alternatives Have Lower Oedema peripheral Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Oedema peripheral Reports All Drugs Causing Oedema peripheral EMPAGLIFLOZIN Demographics